Canaccord Genuity Group Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price

Taysha Gene Therapies (NASDAQ:TSHA) had its price objective boosted by Canaccord Genuity Group from $6.00 to $8.00 in a report issued on Friday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

TSHA has been the topic of several other reports. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Finally, Chardan Capital restated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies presently has an average rating of “Buy” and an average target price of $6.63.

Taysha Gene Therapies Stock Up 10.7 %

TSHA stock opened at $2.28 on Friday. The firm has a 50 day simple moving average of $1.98 and a 200-day simple moving average of $2.38. Taysha Gene Therapies has a twelve month low of $1.19 and a twelve month high of $4.32. The company has a market capitalization of $467.27 million, a P/E ratio of 3.62 and a beta of 0.44. The company has a current ratio of 5.51, a quick ratio of 5.22 and a debt-to-equity ratio of 0.48.

Institutional Investors Weigh In On Taysha Gene Therapies

Several large investors have recently made changes to their positions in TSHA. Bank of New York Mellon Corp bought a new stake in shares of Taysha Gene Therapies during the second quarter valued at about $1,018,000. Creative Planning acquired a new stake in Taysha Gene Therapies in the third quarter worth about $28,000. SG Americas Securities LLC acquired a new stake in Taysha Gene Therapies in the third quarter worth about $129,000. Rhumbline Advisers acquired a new stake in Taysha Gene Therapies in the second quarter worth about $413,000. Finally, Scientech Research LLC bought a new position in shares of Taysha Gene Therapies in the second quarter valued at approximately $97,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.